Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This session will explore how clinical and molecular markers can inform prognosis and therapeutic strategy in chronic hepatitis B. Presentations will compare the impact of current antiviral therapies on hepatocellular carcinoma (HCC) risk and examine how partial virologic responses and HBsAg decline correlate with long-term outcomes. The session will also address the evolving role of therapy discontinuation in HBeAg-negative patients, the utility of quantitative HBsAg and HBV RNA in distinguishing inactive carriers from those with partial cure, and the predictive value of biomarkers in selecting candidates for functional cure.

Presenters in this session will share their research into novel techniques to understand hepatobiliary neoplasia, including the interaction of known carcinnogenic stimuli and the immune system.

This abstract session will present the latest research on complications of portal hypertension, including hepatic encephalopathy, ascites, and HRS-AKI. Authors will present novel findings and innovative approaches in diagnosing and managing these conditions, which are pivotal challenges in patients with advanced liver disease.

This session explores the intersection of mental health, stigma, and innovative care models in chronic liver disease. Presenters will share research and strategies aimed at improving quality of life and clinical outcomes through patient education, timely interventions, and integrated, value-based care.

The therapeutic options for patients with hepatobiliary cancers are expanding, and at the same time the impact of comorbidities on outcomes has become clearer.  Participants will learn about the influence of  MASLD, tumor buden and liver heatlh on treatment success; the potential of immuotherapy in HCC; and consider surgical treatment options in hepatobiliary cancers.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines, antisense oligonucleotides in combination with pegylated interferon, and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.<br />
&nbsp;